News provided by Eli Lilly and Company Jul 23, 2026, 06:45 ET In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist
R., Frias, J
The first GLP-1 receptor agonist, exenatide (Byetta), was FDA-approved on April 28, 2005 built from a peptide isolated in the venom of a Gila monster
Together, they promote recovery, improved sleep, fat loss, and lean muscle development, without overstimulating cortisol or prolactin." Typical protocols: The combination typically uses CJC-1295 (100-300mcg) with Ipamorelin (200-300mcg), often administered together before bed
These include: Desserts, like ice cream and baked goods
Table of Contents Does Semaglutide Work for Weight Loss
